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Summary.-The effect of pre-treatment with Corynebacterium parvum on the
growth in vivo of a range of experimental mouse tumours with differing character-
istics has been investigated. Varying degrees of protection were observed which
were generally greater with the more immunogenic tumours. Administration of
C. parvum 7 days before immunization with irradiated tumour cells diminished the
protective effect which could be obtained by immunization alone. The possible basis
for these seemingly conflicting influences is considered.
HALPERN et al. (1964) showed that a
killed suspension of Corynebacterium
parvum was an unusually potent stimulant
for the reticulo-endothelial (macrophage)
system. A number of associated effects
such as adjuvant activity (Neveu, Branel-
lec and Biozzi, 1964; Biozzi et al., 1966)
and increased resistance to bacterial
(Adlam, Broughton and Scott, 1972) and
protozoal (Nussenzweig, 1967) infection,
have since been reported. The inhibitory
effect of C. parvum pre-treatment on the
growth of a range of experimental mouse
tumours (Sarcoma J, Ehrlich ascites,
a spontaneous mammary carcinoma,
a methylcholanthrene-induced sarcoma
and the AKR leukaemia) has been
described (Halpern et al., 1966; Woodruff
and Boak, 1966; Lamensans et al., 1968).
Although the results obtained here varied
between the different systems, in general,
conditions could be found under which
C. parrum afforded a degree of protection.
Currie and Bagshawe (1970) used a
combination of C. parvum and chemo-
therapy against a methylcholanthrene-
induced fibrosarcoma with some success,
whereas Mathe, Pouillart and Lapeyraque
(1969) were unable to influence an estab-
lished L1210 tumour with a combination
of C. parvum and immunotherapy.
The experiments described here are
concerned with two aspects of the anti-
tumour activities of C. parvum: the effect
of simple pre-treatment and of pre-treat-
ment followed by active immunization on
the growth of a primary tumour challenge.
Several mouse tumour systems, providing
a variety ofgrowth patterns and immuno-
genicities, have been used and the relation-
ship between the effects of C. parvum and
the characteristics of the tumours are
discussed. The investigation formed a
prelude to studies at the cell level and
tissue culture lines have been established
from the tumours described, in order to
facilitate subsequent work in vitro.
MATERIALS AND METHODS
Mice.- Adults of the following inbred
strains and F1 hybrids, maintained in this
Department, were used: CBA-p (from the
Department of Genetics, University of Cam-
bridge), DBA/2 and BALB/c (from the
Chester Beatty Research Institute) and
(BALB/c x DBA/2)F1. Groups of 10 mice
were used for each experimental group
throughout.
Corynebacterium parvrnt. A killed sus-
pension ofC. parvum (Batch No. EZ174 7 mg/S. E. SMITH AND M. T. SCOTT
ml) was provided by Wellcome Research
Laboratories, Beckenham, Kent, England.
A standard dose of 02 ml (1.4 mg) was
injected i.v. or i.p.
Tumourrs.The following tumours were
obtained from the Chester Beatty Research
Institute and maintained in ascitic form in
the mice specified: R-I (radiation induced
CBA leukaemia; Hewitt, 1962) in CBA-p;
Hepatoma 129 (induced by CC13 in a C3H
mouse, Andervont and Dunn, 1955) in CBA-p
and BALB/c; Adj. PC6A (adjuvant induced
BALB/c plasmacytoma, Potter and Robert-
son, 1960) in BALB/c and L5178 (DBA/2
leukaemia, Fischer, 1958) in (BALB/c x
DBA/2)F1.
The CBAT-3 fibrosarcoma was derived
originally from a tissue culture line of CBA
embryo fibroblasts and maintained as a sub-
cutaneous solid tumour in CBA-p mice.
For both routine passage and experi-
mental use, tumours were handled as cell
suspensions in phosphate buffered saline.
Ascites cells were harvested direct and
washed once. Solid tumours were disso-
ciated by mincing with scissors and pipetting
the fragments. The supernatant cells, after
settling, were washed once.
Inactivation of tumour cells.-Cells were
inactivated by in vitro irradiation (15,000
rad) from a 60Co source. This procedure did
not affect the viability of the cells as judged
by trypan blue exclusion.
Assessment of results-Results are dis-
played as curves of percentage of survivors
against days after challenge. Animals whose
deaths are not recorded were kept for 60days.
In the case of the subcutaneous CBAT-3
tumour, a 2 cm diameter was taken as the
endpoint if it occurred before death.
RESULTS
Characteristics of the tumours and their
immunogenicity
Immunogenicity of the various
tumours was assessed by the protective
effect of immunization with inactivated
tumour cells 10 days before challenge
with normal tumour cells. Immunization
against ascitic tumours was i.p., but for
solid tumours the immunizing dose was
split between the i.p. route and a subcuta-
neous (s.c.) site contralateral to that of
the challenge.
RI leukaemia cel1s are syngeneic in
CBA mice and grow rapidly, causing
death from inocula of fewer than 10 cells.
Death is abrupt with only moderate
ascites development, suggesting thatmeta-
stasis is a major factor. The tumour as
first grown here was moderately immuno-
genic in CBA-p mice, a single dose of
105-5 x 105 irradiated cells giving 5000
protection against a 100 cell challenge.
This form of the tumour is referred to as
RI. Weekly passage through mice for
18 months resulted in avariant form which
was very much less immunogenic (RI-
var.); 5 x 105 irradiated RI-var. gave
almost no protection against a 100 cell
challenge. Recourse to frozen stored
material allowed comparisons between
the original and variant forms.
Hepatoma 129 grows rapidly from ino-
cula of less than 10 cells and causes
death with gross ascites and no evidence
of metastases. Our form is not strain
specific; originally a C3H tumour, it is
routinely passaged in CBA against a
minor histocompatibility barrier and a
secondary strain is passaged in BALB/c
mice against a strong histocompatibility
barrier. There is little difference between
the growth rate or minimum lethal dose of
the two strains. The immunogenicity of
irradiated cells is also similar, a dose of
between 104 and 5 x 104 giving 50%
protection against a 100 cell challenge.
The lack of strain specificity is not due to
masking or loss of histocompatibility
antigens, since BALB/c mice were readily
immunized against the tumour by normal
CBA spleen cells.
CBAT-3 fibrosarcoma grows as a
non-metastasizing solid when injected
s.c. Its liability to become haemorrhagic
or to break through the skin makes
quantitative assessment difficult. When
injected i.p. it grows more rapidly as
localized solid tumours in the peritoneal
wall and consistently causes death in the
animals.
Assessment of the immunogenicity of
irradiated cells depends on the route of
injection of challenge cells. Protection
3'62BIOLOGICAL EFFECTS OF CORYNEBACTERIUM PARVUM
is low against s.c. challenge with 104 cells,
106 5 X 106 irradiated cells being required
to give 5000 protection. The titration
with i.p. challenge did not reach an
endpoint but protection was at least 10
times greater.
L5178 leukaemia causes death
essentially by massive i.p. growth with
some local infiltration to form solid
mesenterial growth. The F1 hybrid in
which the tumour was passaged was
within the major histocompatibility group
(H-2d) of the strain of origin (DBA/2),
thus minimizing any potential effects of
allogeneic inhibition. The tumour was
poorly immunogenic in this system and
up to 107 irradiated cells were required
for 500o protection against a 100 cell
challenge.
PC6plassmacytoma gives rise to massive
ascites, with ready formation of a solid
tumour at the injection site; it shows no
evidence of metastasis. It is poorly
immunogenic, with no protection against
a 103 cell challenge with irradiated cell
doses of up to 107.
Protective effects of pre-treatment with C.
parnum
Groups of 10 mice received 0-2 ml of
C. parvum i.v. or i.p. 7 days before
challenge with tumour cells. When C.
parvum is administered 7 days before
injection of sheep red cells it produces a
marked adjuvant effect (Scott, unpub-
lished results).
RI leukaemia.-Challenge doses of
both 10 and 100 cells were assayed (Fig
IA, B). In all cases there was a definite
protective effect from C. parvum which
was highly significant at the lower chal-
lenge dose and with little difference
between the i.v. and i.p. routes of adminis-
tration. It was noticeable that prolonga-
tion of survival of animals incompletely
protected by C. parvum was accompanied
by greater ascites development. Very
little protection from C. parvurn was
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FIG. 1 A-C.-The effect of C. parvum pre-treatment on RI letukaemia in CBA mice. 1-4 mg C. pamvum
7 days before challenge with 100 RI (a), 10 RI (b) and 100 RI-variant (c) leukaemia cells. C.
parvuin i.v. (...... ), C. parvumi? i.p. (-- -), none ( ).
D-F. The effect of combined C. parvumi? pre-treatment and immunization on RI leukaemia in CBA
mice. 1-4 mg C. parvuton i.v. 7 days before immunization i.p. with 5.104 (e), 5.105 (f) irradiated
leiukaemia cells or none (d). All mice were challenged i.p. with 100 RI leukaemia cells after a
fturther 7 days. Untreated mice ( ), immunization alone (- -), C. parvuml + immunliza-
tion (. ).
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FiIG. 2 A-C. The effect of C. parvuin pre-treatment on Hepatoma 129 in CBA (a, b) and BALB/c
(c) mice. 1-4 mg C. parvuem 7 days before challenge with 10 or 100 tumour cells. C. parvum i.v.
( ), C. parvurn i.p. ( - -), none ( ).
D-E. The effect ofcombined C. parvumn pre-treatment and immunization on Hepatoma 129 cells in
BALB/c mice. 1-4 mg C. parvum 7 days before immunization i.p. with 5.104 (d), 5.105 (e) irra-
diated tumour cells. Untreated mice ( ), immunization alone (-+ +- 1). C. parvuwn i.v.
-t immunization (...... ), C. parvumn i.p. + immunization (- - - -).
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FIG. 3. The effect of C. parvum pre-treatment on CBA-T3 fibrosarcoma in CBA mice. 1-4 mg
C. parvurn 7 days before challenge with either 103 or 104 tumour cells s.c. (top row) or i.p. (bottom
row). C. parvurn i.v. ( ), C. parvu?n i.p. ( ). none
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Fio. 4. The effect of C. parvuni pre-treatment on PC6 plasmacytoma in BALB/c mice (left) and
L5178 leukaemia in (BALB/c x DBA/2)Fj (right). 1-4 mg C. parvum 7 days before challenge
i.p. with 103 or 104 PC6, or 100 L5178 cells. C. parumn i.v. (. ), C. parvuin i.p. (
none ( ).
afforded against the poorly immunogenic
RI-var. as compared with the original RI
(Fig. IC).
Hepatoma 129.-Challenges of both
10 and 100 cells in the CBA system and
100 cells in the BALB/c system were
assayed (Fig. 2A-C). In CBA mice the
protective effect was small, with little
difference between C. parvum i.v. and i.p.
The situation was quite different with
BALB/c mice: whereas C. parvum i.v.
had little effect, there was a strong pro-
tective effect following i.p. administration.
CBAT-3 fibrosarcoma. Both s.c. and
i.p. challenge with 103 and 104 cells were
investigated (Fig. 3): s.c. challenge with
103 cells proved too small for analysable
results, although C. parvum pre-treatment
both i.p. and i.v. increased the number of
survivors. At the 104 dose there was a
definite effect with C. parvum i.p. but
very little with i.v. injection. With i.p.
challenge of 103 cells both i.v. and i.p. C.
parvum afforded strong protection. This
protection was maintainedbyi.p. C. parvum
against a 104 cell challenge, but the i.v.
route was again less effective.
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L5178 leukaemia.-The effect of C.
parvum pre-treatment against a 100 cell
challenge was minimal (Fig. 4).
PC6 plasmacytoma. Pre-treatment
again afforded only slighit protection
against challenges of 103 and 104 cells
(Fig. 4).
Combined pre-treatment with C. parvum and
irradiated cells
C. parvum was injected 7 days before
immunization with irradiated cells and
the animals were challenged after a further
7 days. Groups of 10 mice were used.
RI leukaemia. The results of com-
bining immunization by 5 x 104 or
5 x 105 irradiated cells with i.v. C.
parvum are shown in Fig. ID-F. C.
parvum pre-treatment depressed the pro-
tective effect of immunization, more
especially with the lower immunizing dose,
but exerted its normal protective effect
when given alone.
Hepatoma 129. The outcome of
combining immunization with C. parvurn.
pre-treatment was investigated in the
BALB/c system. Two immunizing doses
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TABLE I.-The Protective Effect of C. parvum Pre-treatment Against Experimental
Mouse Tumours of Varying Immunogenicity
Tumour type
* Ascites leukaemia
Fibrosarcoma
Ascites hepatoma
Ascites hepatoma
Ascites leukaemia
Ascites plasmacytoma
Fibrosarcoma
*Fibrosarcoma
Experimental host
and challenge route Immunogenicity*
CBA x x
i.p.
CBA
i.p.
* CBA
l.p.
BALB/c
i.p.
(BALB/c xDBA/2)Fl
i.p.
BALB/c
i.p.
CBA
s.c.
CBA
i.p.
x x x
C. parvumn protectiont
i.V. i.p.
+L .~ -, +F
+ I
x x x
x
x
x x
+ * +
I4 *. +
* Graded according to dose of irradiated tumour cells giving 500% protection against a challenge of
10-20 times the LD50 of living tumour cells: x x x 104-105; X X 105-106; X 106-107.
t Subjective grading from good (±+ + +-) to poor (±) protection.
(5 x 104 and 5 x 105) were used with
both i.v. and i.p. C. parvum (Fig. 2D-E).
Good protection was induced with i.p.
C. parvum alone and such treatment did
not modify the protective effect of
immunization. Administration of C.
parvum i.v., which alone afforded minimal
protection, completely abolished the pro-
tective effect of the lower immunizing
dose ofirradiated cells and slightlyreduced
that of the high dose.
DISCUSSION
C. parvum pre-treatment was found
to confer some degree ofprotection against
a variety of highly adapted and rapidly
growing mouse tumours, in agreement
with reports by previous workers (Halpern
et al., 1966; Woodruff and Boak, 1966;
Lamensans et al., 1968).
It seemed likely that C. parvum would
be more effective against the more
immunogenic tumours and such a correla-
tion is seen in the comparison of the
normal and variant RI strains. The
variation in results obtained with the
different tumour systems serves to em-
phasize the complexity of the mechanisms
involved, but the more striking effects
were found in theimmunologicallyreactive
situations (Table I). C. parvum causes
intense reticulo-endothelial stimulation
(Halpern et al., 1964) and stimulated
macrophages have been reported to be-
come non-specifically cytotoxic to
tumour cells (Alexander and Evans, 1971;
Hibbs, Lambert and Remington, 1972).
Such effects may explain, for example,
the slight protection against the very
poorly immunogenic PC6 tumour, but the
suggested correlation between immuno-
genicity and C. parvum protection implies
involvement of specific immunological
defences in addition to any non-specific
activation.
The i.p. route for C. parvum was
somewhat more effective than the i.v.
although both routes were similar with
respect to spleen and liver enlargement
and neither led to an increased peritoneal
cell population at the time of challenge
(authors' unpublished observations). That
the difference cannot be explained simply
by local i.p. effects is also shown by the
greater efficacy of i.p. C. parvum in the
s.c. CBAT-3 system.
In view of the known adjuvant
activity of C. parvum, it was anticipated
that combination with immunization
would result in increased protection com-
pared with the latter alone. However,
in both the systems investigated, i.v.
Tumour and
strain of
origin
RI
CBA
RI-var.
CBA
H129
C3H
H129
C3H
L5178
DBA/2
PC6
BALB/e
CBAT-3
CBA
CBAT-3
CBA
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C. parvum, given before immunization,
decreased the protective effect, although
i.p. C. parvum in the H129 system did not
influence the immune response. It seems
that while C. parvum treatment stimulates
the defences of the host against many
tumours it may also, at least when given
i.v., concomitantly depress some part
of the immune response. Preliminary
experiments both in vitro and in vivo have
so far failed to reveal evidence for produc-
tion of enhancing antibody and the fact
that the depression can be overridden by
largerimmunizingdosesalsoargues against
such a mechanism. Enhanced growth of
allogeneic tumour cells following immuni-
zation in conjunction with either complete
or incomplete Freund's adjuvant has
recently been reported (Zola, 1972), and
again no evidence of enhancing antibody
could be found, the effect being attributed
to depression ofcell-mediatedcytotoxicity.
Evidence of depressed cell-mediated (T
lymphocyte) responsesfollowingC.parvum
treatment comes from the demonstration
of reduced delayed hypersensitivity
(Asherson and Allwood, 1971), PHA
responsiveness and GVH reactivity of
lymphocytes (Scott, 1972).
Schedules for the immunotherapeutic
treatment of human tumours have often
included adjuvants, and C. parvum has
begun tofigure among these (Mathe, 1971).
The presentfindingthat this agent, atleast
under certain experimental conditions, can
show an immunosuppressive component
in its action urges caution in this field.
We wish to acknowledge the able
technical assistance of Mrs S. Wishart and
Miss C. Tieman. Thanks are also due to
Dr J. G. Howard for helpful criticism.
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